M&A by necessity: Takeda and Shire
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
Thomas Cueni on pricing and developing markets
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models,…
Switzerland: The Advent of Drone Delivery
As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for…
FarmaMondo: Bringing Responsible Access Global
With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try…
Italian Switzerland: Creativity & Excellence
The southern Swiss canton of Ticino does not have the life science reputation of Basel, Zurich or Geneva, but benefits from an open business environment, strategic location, and a thriving network…
Swiss Biotech’s Funding Quandary
Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an…
Why the J&J Takeover of Actelion Looks Unlikely
Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20…
Mapping Swiss Pharma
It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and…
Switzerland: Europe’s Brain
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Switzerland: Europe's Brain
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Switzerland: A Hotbed of Innovation
Switzerland’s especially fine reputation for research impact and innovation generation is attracting a host of MNCs to base their European headquarters in the mountain nation and spend big on world-leading…
Biogen’s Billion Dollar Swiss Investment
Biologics giant Biogen is investing USD one billion in a next-generation manufacturing facility in Luterbach, near Solothurn, Switzerland, tripling production capacity and creating 400 new jobs. The decision to situate…